Sign in
Taking peopleNo phase

Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Key facts

Who runs it
HighLife SAS
Where
Australia, Belgium, France, Germany, Poland, Singapore, and United Kingdom48 sites in 7 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
120 people, planned
Started
28 May 2019
Expected to end
15 Dec 2031
Type of study
Interventional
Treatments tested
  • HighLife Transcatheter Mitral Valve Replacement
Record updated
15 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • 1. Age ≥ 18 years 2. Moderate-severe or severe mitral regurgitation (≥ 3+) 3. Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV 4. Patient is under guideline directed medical therapy, as reviewed and confirmed by the local multidisciplinary Heart Team, for at least one month 5. Patient is high-risk for open-heart surgery based on the assessment of the multidisciplinary Heart Team using standard scoring systems and consideration of co-morbidities, frailty, and disability 6. Patient meets the anatomical criteria for HighLife valve 7. Patient is willing to participate in the study and provides signed informed consent

Who cannot take part

  • Patient cannot tolerate anticoagulation or antiplatelet therapy
  • Any stroke/TIA within 30 days
  • Active infections requiring antibiotic therapy
  • Active ulcer or gastro-intestinal bleeding in the past 3 months
  • History of bleeding diathesis, coagulopathy or refusal of future blood transfusion
  • Patient has known allergies to the device components or contrast medium
  • Patients with a life expectancy of less than 12 months due to non-cardiac conditions
  • Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months; -
  • Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)
  • Patients in whom TEE is not feasible
  • Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months
  • Patient is unable to comply with the follow-up schedule and assessments
  • Participation in another clinical investigation at the time of inclusion

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

to evaluate the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment.

The group in the trial

  • Single armOther group

    Single arm, non-randomized

    Treatment: HighLife Transcatheter Mitral Valve Replacement

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
15 September 2025